推薦產品
產品名稱
来曲唑, ≥98% (HPLC)
化驗
≥98% (HPLC)
形狀
powder
顏色
white to off-white
溶解度
DMSO: >50 mg/mL
起源
Novartis
儲存溫度
2-8°C
SMILES 字串
N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
InChI
1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
InChI 密鑰
HPJKCIUCZWXJDR-UHFFFAOYSA-N
基因資訊
human ... CYP19A1(1588)
尋找類似的產品？ 前往 產品比較指南
應用
来曲唑已用于：
- 在类器官生长试验中测定其抑制力（48）
- 研究类固醇受体共激活因子1（SRC-1）介导的海马PSD-95内源性雌激素调节作用（49）
- 研究其对肿瘤诱导的痛觉过敏的作用 （50）
- 对大鼠进行激素干预（51）研究其对脂质运载蛋白-2（Lcn2）的作用（52）研究其对机械痛觉过敏和芳香化酶表达的作用（53）
生化／生理作用
来曲唑是一种佐剂，可用于治疗乳腺癌。[1]
来曲唑是一种非甾体芳香酶抑制剂。
来曲唑是第三代非甾体芳香酶抑制剂。 它是芳香酶系统的竞争性抑制剂，因此可抑制雄激素向雌激素转化。来曲唑通过竞争性结合到该酶的细胞色素P450亚基的血红素上而抑制芳香酶，导致所有组织中雌激素的生物合成减少。
訊號詞
Warning
危險聲明
危險分類
Repr. 2 - STOT RE 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
客戶也查看了
Bianca Posocco et al.
PloS one, 15(2), e0228822-e0228822 (2020-02-08)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice
Natalia Lagunas et al.
Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)
Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible
Zahra Shaaban et al.
Iranian journal of basic medical sciences, 25(1), 110-120 (2022-06-04)
Despite prevalence of polycystic ovary syndrome (PCOS) among childbearing women and development of many animal models for this syndrome, information on its etiology is still scarce. The intrauterine hyperandrogenic environment may underlie changes at the level of hypothalamus, pituitary, ovary
Drugs for Pregnant and Lactating Women E-Book (2009)
G Allevi et al.
British journal of cancer, 108(8), 1587-1592 (2013-04-13)
The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response. This single institution
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
